26046-90-2
26046-90-2 結(jié)構(gòu)式
基本信息
甲基硒代半胱胺酸
3-甲基硒代-L-丙氨酸
3-(甲基硒基)-L-丙氨酸
SE-甲基硒代-L-半胱氨酸
SE-(甲基)硒基-L-半胱氨酸
3-(甲基硒基)-L-氨基丙羧酸
3-甲基硒代-L-D-Α-氨基羧酸
SE-(甲基)硒基-L-半胱氨酸
METHYLSELENO-L-CYSTEINE
L-Se-Methylselenocysteine
SE-METHYLSELENO-L-CYSTEINE
3-(METHYLSELENO)-L-ALANINE
3-(Methylselanyl)-L-alanine
SELENIUMMETHYLSELENOCYSTEINE
SE-METHYLSELENO-L-CYSTEINE 98%
Se-methylseleno-L-cysteine,98%
L- selenium - methyl selenocysteine
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
常見問題列表
3-(甲基硒基)-L-丙氨酸又叫L-硒甲基硒代半胱氨酸，常用作硒營養(yǎng)強(qiáng)化劑。它是第21種人體必需氨基酸—L-硒代半胱氨酸的硒甲基化衍生物，它廣泛存在于黃芪、大蒜、洋蔥和椰菜等植物以及富硒酵母中，具有化學(xué)結(jié)構(gòu)明確、毒性小、生物利用率高、補(bǔ)硒效果好等優(yōu)點，不僅對多種腫瘤（如乳腺癌，前列腺癌，肝癌等）有預(yù)防作用，而且對癌癥治療有輔助作用，具有廣闊的應(yīng)用前景。
2002年，硒-甲基硒代半胱氨酸被美國FDA認(rèn)定為最新一代硒源類飲食補(bǔ)充劑；2009年3-(甲基硒基)-L-丙氨酸被我國衛(wèi)生部批準(zhǔn)為新型營養(yǎng)強(qiáng)化劑（食品添加劑新品種2009年第11號公告）。
2-氨基-3-甲基硒基丙酸是DMBA誘導(dǎo)的乳腺腫瘤的抑制劑。
Se-Methylselenocysteine (100-400 μM; 3 days) induces apoptosis in SKOV-33 cells.
Se-Methylselenocysteine (100-400 μM; 3 days) induces caspase-3 mediated apoptosis.
Apoptosis Analysis
| Cell Line: | SKOV-3 cells |
| Concentration: | 100, 200, 400 μM |
| Incubation Time: | 3 days |
| Result: | Resulted in a markedly increased accumulation of Sub-G1 phase, which occurred in both SeMSC concentration and culture time-dependent. |
Western Blot Analysis
| Cell Line: | SKOV-3 cells |
| Concentration: | 100, 200, 400 μM |
| Incubation Time: | 3 days |
| Result: | Resulted in a decrease in the expression of the 32 kDa form of procaspase-3. |
Se-Methylselenocysteine (0.2?mg/mouse; p.o.; daily for 14 days) potentiates the antitumour activity of CDDP and Cyclophosphamide in nude mice bearing human FaDu and A253 head and neck xenografts.
Alzheimer's disease (AD) mice are treats with Se-Methylselenocysteine (0.75 mg/kg BW per day) in their drinking water for 10 months. Se-Methylselenocysteine reduces oxidative stress and neuro-inflammation; Se-Methylselenocysteine modulates the distribution and levels of several metal ions; Se-Methylselenocysteine decreases amyloid-β peptide (Aβ) generation by inhibiting the expression of its precursor protein APP and β-secretase (BACE1), and attenuates tau hyperphosphorylation and neurofibrillary tangles (NFT) formation via promoting protein phosphatase 2A (PP2A) activity, thereby preserving synaptic proteins and neuron activities and finally improving spatial learning and memory deficits in AD model mice.
| Animal Model: | Female athymic nude mice (bearing human A253 and FaDu squamous cell carcinoma xenografts) |
| Dosage: | 0.2?mg/mouse |
| Administration: | p.o.; daily for 14 days (7 days before and 7 days after Cyclophosphamide or CDDP in a total of 14 days) |
| Result: |